280 related articles for article (PubMed ID: 15337796)
1. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.
Fromme EK; Eilers KM; Mori M; Hsieh YC; Beer TM
J Clin Oncol; 2004 Sep; 22(17):3485-90. PubMed ID: 15337796
[TBL] [Abstract][Full Text] [Related]
2. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
3. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
Easson AM; Bezjak A; Ross S; Wright JG
Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
[TBL] [Abstract][Full Text] [Related]
4. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires.
Jensen K; Bonde Jensen A; Grau C
Radiother Oncol; 2006 Mar; 78(3):298-305. PubMed ID: 16524633
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
[TBL] [Abstract][Full Text] [Related]
6. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma.
Cocks K; Cohen D; Wisløff F; Sezer O; Lee S; Hippe E; Gimsing P; Turesson I; Hajek R; Smith A; Graham L; Phillips A; Stead M; Velikova G; Brown J;
Eur J Cancer; 2007 Jul; 43(11):1670-8. PubMed ID: 17574838
[TBL] [Abstract][Full Text] [Related]
7. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Gravis G; Marino P; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Fizazi K
Eur J Cancer; 2014 Mar; 50(5):953-62. PubMed ID: 24424105
[TBL] [Abstract][Full Text] [Related]
8. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy.
Allal AS; Sprangers MA; Laurencet F; Reymond MA; Kurtz JM
Br J Cancer; 1999 Jul; 80(10):1588-94. PubMed ID: 10408404
[TBL] [Abstract][Full Text] [Related]
9. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.
Greimel ER; Kuljanic Vlasic K; Waldenstrom AC; Duric VM; Jensen PT; Singer S; Chie W; Nordin A; Bjelic Radisic V; Wydra D;
Cancer; 2006 Oct; 107(8):1812-22. PubMed ID: 16977652
[TBL] [Abstract][Full Text] [Related]
10. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.
Butler L; Bacon M; Carey M; Zee B; Tu D; Bezjak A
J Clin Oncol; 2004 Jun; 22(12):2461-8. PubMed ID: 15197209
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTC.
Scalliet PG; Remouchamps V; Curran D; Ledent G; Wambersie A; Richard F; van Cangh P
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1549-61. PubMed ID: 15050336
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
13. Quality of life of head and neck cancer patient: validation of the European organization for research and treatment of cancer QLQ-C30 and European organization for research and treatment of cancer QLQ-H&N 35 in Indian patients.
Chaukar DA; Das AK; Deshpande MS; Pai PS; Pathak KA; Chaturvedi P; Kakade AC; Hawaldar RW; D'Cruz AK
Indian J Cancer; 2005; 42(4):178-84. PubMed ID: 16391435
[TBL] [Abstract][Full Text] [Related]
14. Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires for Arabic-speaking Populations.
Awad MA; Denic S; El Taji H
Ann N Y Acad Sci; 2008 Sep; 1138():146-54. PubMed ID: 18837895
[TBL] [Abstract][Full Text] [Related]
15. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer--15 years' follow-up. A comparison with age-matched controls.
Fransson P
Acta Oncol; 2008; 47(5):852-61. PubMed ID: 17899451
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life among patients with metastatic prostate cancer.
Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
[TBL] [Abstract][Full Text] [Related]
18. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
19. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.
van Andel G; Bottomley A; Fosså SD; Efficace F; Coens C; Guerif S; Kynaston H; Gontero P; Thalmann G; Akdas A; D'Haese S; Aaronson NK
Eur J Cancer; 2008 Nov; 44(16):2418-24. PubMed ID: 18774706
[TBL] [Abstract][Full Text] [Related]
20. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.
Brown J; Thorpe H; Napp V; Fairlamb DJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG; Stephens RJ; Waller D; West P; Peake MD
J Clin Oncol; 2005 Oct; 23(30):7417-27. PubMed ID: 16157935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
